慢性乙型肝炎口服治疗5年后肝细胞癌预测:大型白种人队列研究
该研究基于PAGE-B队列中1,427例完成5年以上口服抗病毒治疗且5年内未发生肝细胞癌的白种人慢性乙型肝炎患者,中位随访8.4年,评估5年后肝细胞癌的预测因素。年龄>50岁、基线肝硬化和第5年肝脏硬度≥12 kPa为独立危险因素,据此开发的CAGE-B和SAGE-B评分可有效预测5年后肝细胞癌风险。
要点
- 年龄>50岁、基线肝硬化、第5年肝脏硬度≥12 kPa是治疗5年后肝细胞癌的独立危险因素。
- CAGE-B和SAGE-B评分在低危组中对肝细胞癌的阴性预测值均为100%。
- 基线肝硬化患者若第5年肝脏硬度<12 kPa,肝细胞癌风险较低,但仍可能需要监测。
核心结论
- 在白种人慢性乙型肝炎患者中,口服抗病毒治疗5年后肝细胞癌风险取决于年龄、基线肝硬化状态和第5年肝脏硬度。
- CAGE-B和SAGE-B是简单可靠的评分,可用于预测治疗5年后的肝细胞癌风险并指导监测。
研究设计与样本
- 研究纳入PAGE-B队列中1,951例成年白种人慢性乙型肝炎患者,其中1,427例(73%)完成>5年随访且5年内未发生肝细胞癌。
- 从治疗开始中位随访8.4年,开发基于评分的风险评分以预测第5年后的肝细胞癌风险。
主要发现
- 在第5-12年期间,33/1,427例(2.3%)患者诊断为肝细胞癌,第8、10、12年累积发病率分别为2.4%、3.2%和3.8%。
- 年龄较大或年龄>50岁、基线肝硬化和第5年肝脏硬度≥12 kPa与肝细胞癌风险增加独立相关。
- 非肝硬化患者中,第5年肝脏硬度<12 kPa者肝细胞癌发病率低于肝硬化患者;基线肝硬化患者中,第5年肝脏硬度<12 kPa者发病率低于≥12 kPa者。
- CAGE-B评分基于第5年年龄和基线肝硬化与第5年肝脏硬度的关系,SAGE-B评分仅基于第5年年龄和肝脏硬度,c-index为0.809-0.814、0.805-0.806(bootstrap验证后)。
- 两种评分在低风险组中对肝细胞癌发展的阴性预测值均为100%。
关键数值与推荐
- 肝细胞癌独立危险因素:年龄>50岁、基线肝硬化、第5年肝脏硬度≥12 kPa。
- CAGE-B评分基于第5年年龄和基线肝硬化与第5年肝脏硬度的关系;SAGE-B评分仅基于第5年年龄和肝脏硬度。
- CAGE-B和SAGE-B评分的c-index分别为0.809-0.814和0.805-0.806,bootstrap验证后为0.805-0.806(原文合并报告,未区分)。
- 低风险组阴性预测值均为100%。
临床怎么用
- 对于完成5年口服抗病毒治疗的慢性乙型肝炎患者,可使用CAGE-B或SAGE-B评分评估5年后肝细胞癌风险。
- 低风险组患者(阴性预测值100%)可能无需继续肝细胞癌监测,但需结合临床判断。
- 基线肝硬化且第5年肝脏硬度<12 kPa者肝细胞癌风险较低,但仍可能需要监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) may develop in patients with chronic hepatitis (CHB) even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors of HCC development and the need for HCC surveillance in this setting. METHODS: Of 1,951 adult Caucasians with CHB included in the PAGE-B cohort, 1,427 (73%) had completed >5 years of follow-up under therapy without developing HCC by year 5. Median follow-up was 8.4 years from treatment onset. Points-based risk scores were developed to predict HCC risk after year 5. RESULTS: In years 5-12, HCC was diagnosed in 33/1,427 (2.3%) patients with cumulative incidences of 2.4%, 3.2% and 3.8% at 8, 10 and 12 years, respectively. Older age or age >50 years, baseline cirrhosis and liver stiffness (LSM) ≥12 kPa at year 5 were independently associated with increased HCC risk. The HCC incidence was lower in non-cirrhotics than cirrhotics at baseline with year-5 LSM <12; among cirrhotics at baseline, it was lower in those with year-5 LSM <12 than ≥12 kPa. CAGE-B score was based on age at year 5 and baseline cirrhosis in relation to LSM at year 5 and SAGE-B score was based only on age and LSM at year 5 (c-index = 0.809-0.814, 0.805-0.806 after bootstrap validation). Both scores offered 100% negative predictive values for HCC development in their low risk groups. CONCLUSIONS: In Caucasians with CHB, the HCC risk after the first 5 years of antiviral therapy depends on age, baseline cirrhosis status and LSM at year 5. CAGE-B and particularly SAGE-B represent simple and reliable risk scores for HCC prediction and surveillance beyond year 5 of therapy. LAY SUMMARY: In Caucasians with chronic hepatitis B, the risk of hepatocellular carcinoma after the first 5 years of entecavir or tenofovir therapy depends on age, baseline cirrhosis status and liver stiffness at year 5, which can provide simple and reliable risk scores for hepatocellular carcinoma prediction and surveillance beyond year 5. In patients with cirrhosis at baseline, liver stiffness <12 kPa at year 5 is associated with lower HCC risk, but surveillance may be still required.
引用
- Papatheodoridis GV, Sypsa V, Dalekos GN, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol. 2020. PMID: 31981727. doi:10.1016/j.jhep.2020.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。